Newsletter | February 12, 2025

02.12.25 -- How Did Clinical Researchers Actually Use AI In 2024?

DECENTRALIZED TRIALS

How AI Will Transform Health Equity In Clinical Trials In 2025

Guest Column | By Shaheen Lakhan, MD, Ph.D., Click Therapeutics

Click Therapeutics' CMO/CSO Shaheen Lakhan, MD, Ph.D., FAAN explains how the shift toward AI is the first step in addressing diversity in clinical trials.

Empowering Clinical Trials With Better Devices, Data, And Solutions

Podcast | IQVIA Research & Development Solutions

In part three of this podcast series, Jeff Noll from IQVIA discusses case studies of solutions customers are asking for right now in the sensors and  wearables space and what the future may hold.

TRIAL MANAGEMENT

How Did Clinical Researchers Actually Use AI In 2024?

Guest Column | As told to Abby Proch, Clinical Leader

Looking ahead to 2025, Clinical Leader seeks to understand how clinical research professionals are incorporating AI. So we asked them, “Simply put: Are you using any iteration of AI in your role within clinical research? If so, how and why?”

Triple-Negative Breast Cancer: Global Clinical Trial Landscape

Q&A | Novotech

Triple-Negative Breast Cancer (TNBC) requires new and innovative treatments, such as biomarker-driven therapies, to enhance precision medicine and improve patient outcomes.

Daring To Learn From Failure: The Future Of Stem Cell Therapy

Article | Biorasi

Stem cell therapy has already revolutionized the field of oncology. But where do we go from here? Dr. Robert S. Negrin addresses three key areas of CAR T-cell therapy on the brink of innovation.

2024 Market Trends Survey Results: 5 Clinical Trial Trends To Watch

Webinar | Greenphire

This insightful roundtable discussion delves into the findings from Greenphire’s 2024 Market Trends Survey. Experts uncover the key challenges and priorities shaping clinical trials in 2025.

Top 5 Challenges For Pursuing IO Therapy Clinical Trials

Article | By Erin Finot, MS, MBA, IQVIA Biotech

By leveraging tailored approaches to tackle scientific and operational challenges, sponsors can enhance trial efficiency and advance the development of groundbreaking therapies.

Factors Affecting Systemic Drug Exposure

Article | Altasciences

Understand intrinsic and extrinsic factors that can alter drug exposure, including drug-drug interactions (DDIs), to minimize adverse effects and maximize response.

CHOOSE YOUR OWN ADVENTURE

You're receiving the Wednesday edition of the Clinical Leader newsletter, focusing on Decentralized Trials and Trial Management. To make changes to your newsletter selections, update your topic preferences.

  • Clinical Sites | Patient Centricity | Patient Recruitment (Monday)
  • Clinical Trial Technology (Tuesday)
  • Decentralized Trials | Trial Management (Wednesday)
  • Outsourcing Models | Regulatory & Compliance (Thursday)
  • Clinical Data Management & Analytics | Trial Monitoring (Friday)

Learn more about our personalized newsletters here.

Connect With Clinical Leader: